What's new

[PIO] EMA recommends measures to minimise risk of serious adverse events for Janus kinase inhibitors in chronic inflammatory diseases

31101.jpg




The EMA Safety Committee (PRAC) has recommended measures to minimise the risk of serious adverse events associated with Janus kinase inhibitors (JAK) which are used to treat several chronic inflammatory disorders. These side effects include cardiovascular disease, blood clots, cancer and serious infections.

The Commission recommended that these medicines should be given only if suitable alternative treatment options are not available in the following patient populations: people aged 65 and over, people at increased risk of serious cardiovascular problems (such as heart attack or stroke), existing smokers or people who have been smokers for a long time in the past, and those at increased risk of cancer.

The Committee additionally recommended cautious use of JAK inhibitors in patients with risk factors for blood clots in the lungs and deep veins (venous thromboembolism, VTE). In addition, doses should be reduced in certain groups of patients who may be at risk of VTE, cancer or serious cardiovascular problems.

The recommendations follow a review of available data, including final results from a clinical trial of the JAK inhibitor Xeljanz (tofacitinib) and preliminary findings from an observational study of another JAK inhibitor, Olumiant (baricitinib). During the review, PRAC consulted an expert panel of rheumatologists, dermatologists, gastroenterologists and patient representatives.

The review confirmed that Xeljanz compared to TNF-alpha inhibitors increases the risk of serious cardiovascular problems, cancer, VTE, serious infections and death from any cause. PRAC concluded that these safety findings apply to all approved uses of JAK inhibitors in chronic inflammatory disorders (rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, axial spondylarthritis, ulcerative colitis, atopic dermatitis and pollen alopecia).

Product information for JAK inhibitors used to treat chronic inflammatory disorders will be updated with new recommendations and warnings. In addition, educational materials for patients and healthcare professionals will be revised accordingly. Patients who have questions about their treatment or the risk of serious side effects should contact their physician.

More about the drugs

The Janus kinase inhibitors subject to this review are Cibinqo (abrocitinib), Jyseleca (filgotinib), Olumiant (baricitinib), Rinvoq (upadacitinib) and Xeljanz (tofacitinib). These drugs are prescribed to treat several chronic inflammatory disorders (rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, axial spondylarthritis, ulcerative colitis, atopic dermatitis and pollen alopecia). The active substances of these drugs act by inhibiting the action of enzymes known as Janus kinases. These enzymes play an important role in the inflammation process that occurs in these disorders. By inhibiting the action of the enzymes, the drugs help reduce inflammation and other symptoms of these disorders.

Some JAK inhibitors (Jakavi and Inrebic) are used to treat myeloproliferative disorders. The review did not include these drugs. The review also did not cover the use of Olumiant in the short-term treatment of COVID-19, which is under evaluation by the EMA.

More about the process

The review of JAK inhibitors in the treatment of inflammatory disorders was initiated at the request of the European Commission (EC) under the Article 20 of Regulation (EC) No 726/2004.

The review was conducted by the Pharmacovigilance and Risk Assessment Committee (PRAC), the committee responsible for assessing safety issues for medicinal products for human use, which will make a number of recommendations. The PRAC recommendations will now be sent to the Committee for Medicinal Products for Human Use (CHMP), responsible for questions relating to medicinal products for human use, which will issue a final legally binding decision applicable to all EU Member States in due course. The final stage of the review process is the adoption by the EU of a legally binding decision applicable to all EU Member States.

(AF)
Contents of this article including associated images are owned by PIO
Views & opinions expressed are those of the author and/or PIO

Source

[/URL][/P]
 
Back
Top